Alkermes Announces Initiation Of Phase 1 Clinical Study Of ALKS 37 For The Treatment Of Opioid-Induced Constipation
Alkermes, Inc. (NASDAQ: ALKS) announced the initiation of a phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the opioid agonist effects on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC).
Related Posts
Tags: alkermes, alks, clinical, constipation, induced, initiation, opioid, phase, study, treatment
This entry was posted on Friday, October 30th, 2009 at 5:10 pm and is filed under Analgesics Pain Migraine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.



